Drugs / Secretory Leukocyte Protease Inhibitor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00005569 | Apr 2000 → Jul 2003 | — | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Secretory Leukocyte Protease Inhibitor | “SLPI (Secretory Leukocyte Protease Inhibitor)” NCT00005569 ↗ |
| Known as | SLPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005569 ↗ |
| Action | Inhibit | “reduced elastase activity” NCT00005569 ↗ |
| Modality | Peptide | “SLPI peptide” NCT00005569 ↗ |
| Route | Topical | “applied topically” NCT00005569 ↗ |